
Clinical Trials - May 28, 2014
Adenovir Pharma raises MSEK 10 to complete phase II study and prepare for exit
The Swedish pharmaceutical development company Adenovir Pharma has raised SEK 10 million via a rights issue to fund completion of an ongoing clinical phase II study for treatment of infectious eye disease and to prepare for exit. If successfully developed, drug candidate, APD-209 could become the first effective antiviral treatment of EKC and it could solve […]

Clinical Trials - April 29, 2014
Adenovir starts phase II clinical study
The Swedish pharmaceutical development company Adenovir Pharma has started a phase II clinical study for the treatment of an infectious eye disease. Adenovir has already completed a clinical phase I study among 48 healthy volunteers and showed that the drug candidate is safe and well tolerated. The company is now continuing the development of a pharmaceutical […]

Clinical Trials - January 28, 2014
Adenovir Pharma has started a phase II clinical study
The Swedish pharmaceutical development company Adenovir Pharma has started a phase II clinical study for the treatment of an infectious eye disease. Caused by adenoviruses, millions of people are infected every year by epidemic keratoconjunctivitis (EKC). There are currently no effective antiviral treatments available. Adenovir has already completed a clinical phase I study among 48 […]